Group 1 - The core point of the article is that Dirui Medical (300396) reported a total of 15,985 shareholders as of February 13, 2026 [1]

Core Viewpoint - Dier Medical faces significant challenges, including its first annual loss since its listing, due to internal control issues and a declining market environment in the IVD industry [1][2][7] Group 1: Financial Performance - In 2025, Dier Medical's revenue is projected to decline by 60.12% year-on-year to 469 million yuan, with a net profit of -87 million yuan, marking a 145.31% year-on-year decrease [2][4] - The company anticipates a total loss of at least 1 billion yuan in Q4 2025, with no signs of stabilization [4] - The operating cash flow has seen a net outflow of 580 million yuan in the first three quarters of 2025, following a 299 million yuan outflow in 2024 [4] Group 2: Market Environment - The IVD industry is experiencing a downturn, with A-share IVD sector revenues dropping by 14.5% year-on-year to 27.62 billion yuan in the first three quarters of 2025, and net profits down by 26.4% to 4.49 billion yuan [2] - Dier Medical's performance is lagging behind the industry, with its revenue and profit both declining significantly [2] Group 3: Operational Challenges - The company's gross margin for instrument business plummeted from 33.99% in 2023 to 9.68% in the first half of 2025, while reagent gross margin fell from 75.42% to 60.53% [4] - Dier Medical's business structure is heavily weighted towards instruments rather than reagents, which is contrary to the industry norm of "instruments attract customers, reagents generate profit" [4][5] Group 4: Internal Control Issues - The company received a corrective order from the Jilin Securities Regulatory Bureau for improper revenue recognition and inadequate internal controls, leading to an overstatement of revenue by 3.693 million yuan and profit by 716,000 yuan in 2023 [1][7] - The company has reported a significant increase in credit impairment losses and asset impairment losses, totaling over 25.8 million yuan in the first three quarters of 2025 [5] Group 5: Governance and Strategic Challenges - Despite the acquisition by China Resources Group for 1.8 billion yuan, the expected synergies have not materialized, and the company's performance continues to decline [8] - Dier Medical has launched 14 new products in 2025, but faces stiff competition from domestic leaders and foreign brands in high-end markets [9]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2026-006 迪瑞医疗科技股份有限公司 关于变更医疗器械生产许可证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 企业负责人：郎涛 生产地址：长春市高新技术产业开发区云河街 95 号；长春市高新技术产业 开发区宜居路 3333 号；长春市高新区卓越东街与宜居路交汇北行 200 米创投高 新产业园 5#楼；长春市朝阳经济开发区阜育西街与兴民南路交汇苏宁物流中心 的普洛斯普易长春朝阳物流园园区 1#仓库（二期）号 1 分区单元、1#仓库（二 期）号 2 分区单元。 生产范围： 2017 分类目录：II 类：22-01-血液学分析设备；22-02-生化分析 设备；22-03-电解质及血气分析设备；22-04-免疫分析设备；22-09-尿液及其他样 本分析设备；22-10-其他医用分析设备；22-15-检验及其他辅助设备；6840-体外 诊断试剂；III 类：6840-体外诊断试剂*** 住所：长春市高新技术产业开发区云河街 95 号 许可期限：自 2025 年 2 月 28 日至 2030 年 2 月 ...

经济观察网迪瑞医疗（300396）因2023年涉外销售订单收入确认不审慎，导致多记营业收入369.30万 元、多记营业利润71.60万元，同时涉外销售内部控制不完善，被吉林证监局采取责令改正措施，并对 时任总经理王学敏、副总经理牛丹丹、财务总监张兴艳出具警示函，均记入证券期货市场诚信档案。公 司表示将整改，此事件不影响正常经营管理。 近7天(2026年2月5日至11日)，迪瑞医疗股价波动明显。2月5日收盘价13.27元，2月11日收盘价13.17 元，期间股价最高为13.45元，最低为13.11元。成交量方面，2月5日成交206.08万股，2月11日成交 176.41万股，整体交投活跃度适中。截至2月11日，市盈率为负值，反映盈利承压。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势 ...

Core Viewpoint - The Jilin Securities Regulatory Bureau has imposed corrective measures on Dirui Medical Technology Co., Ltd. due to improper revenue recognition and inadequate internal controls regarding foreign sales orders, leading to overstated revenue and profits in 2023 [1][2]. Group 1: Revenue Recognition Issues - Dirui Medical recognized revenue from certain foreign sales orders without actual customs clearance and subsequently returned the goods, resulting in an overstatement of operating revenue by 3.693 million yuan and operating profit by 716,000 yuan for 2023 [1]. - This practice violates the relevant provisions of the Accounting Standards for Enterprises and the Information Disclosure Management Measures [1]. Group 2: Internal Control Deficiencies - The company has incomplete documentation for some foreign sales orders, which does not comply with the Basic Norms for Internal Control and related application guidelines [1]. - The then General Manager Wang Xuexin, Deputy General Manager Niu Dandan, and Chief Financial Officer Zhang Xingyan are held primarily responsible for these issues [1][2]. Group 3: Regulatory Actions - The Jilin Securities Regulatory Bureau has mandated corrective administrative measures for Dirui Medical and issued warning letters to the responsible executives, which will be recorded in the securities market integrity archives [2]. - As of September 30, 2025, China Bank Co., Ltd. - Dacheng Jingheng Mixed Securities Investment Fund holds 0.47% of Dirui Medical's shares, making it the 9th largest shareholder [2][3].

蓝鲸新闻2月11日讯，近日，吉林证监局发布行政监管措施决定书，剑指迪瑞医疗科技股份有限公司及相关责任人。 决定书显示，迪瑞医疗科技股份有限公司存在以下问题： 一、公司涉外销售订单收入确认不审慎。公司2023年存在部分涉外销售订单确认收入后，对应商品未实际报关并办理退货情形。导致公司2023 年多记营业收入369.30万元，多记营业利润71.60万元。 二、公司涉外销售内部控制不完善，部分涉外销售订单相关资料保存不完整。 ( 令改正行政监管措施并记入证券期货市场诚信档案，对王学敏、牛丹 丹、张兴艳采取出具警示函监管措施并记入证券期货市场诚信档案。 你公司及相关人员应充分汲取教训，严格遵守证券期货法律法规，审 慎执行企业会计准则有关规定,加强公司内部控制,杜绝此类行为再 次发生，并在收到本决定书之日起30日内向我局提交整改报告。 如对本监管措施不服，可在收到本决定书之日起60日内向中国证券监 督管理委员会提出行政复议申请,也可以在收到本决定书之日起6个月 内向有管辖权的人民法院提起行政诉讼。复议与诉讼期间，上述监督 管理措施不停止执行。 吉林证监局 2026年2月5日 上述情况不符合《企业内部控制基本规范》《企业 ...

Group 1 - The company, Dirui Medical, responded to investor inquiries on February 9, indicating that product information should be based on the company's regular reports [2]

Core Viewpoint - The company, Dirui Medical Technology Co., Ltd., has received administrative regulatory measures from the Jilin Securities Regulatory Bureau due to issues related to the recognition of foreign sales order revenues and inadequate internal controls, leading to corrective actions and warnings issued to three responsible individuals [1][2][3] Group 1: Regulatory Issues - The company was found to have recognized revenue from foreign sales orders without proper prudence, resulting in an overstatement of operating revenue by 3.693 million yuan and operating profit by 716,000 yuan for the year 2023 [1][3] - Inadequate internal controls were identified, with incomplete documentation related to some foreign sales orders [2][3] Group 2: Consequences and Company Profile - The overstatement of operating revenue of 3.693 million yuan represents 0.27% of the company's total operating revenue for 2023 [3] - The Jilin Securities Regulatory Bureau has mandated corrective actions and recorded the penalties in the securities and futures market integrity archives for the company and the responsible individuals [3] - Dirui Medical specializes in the research, production, marketing, and service of medical testing instruments and related reagents, having entered the capital market in 2014 [3] - As of February 9, 2026, the company's stock price was 13.34 yuan, with a total market value of 3.638 billion yuan, reflecting a cumulative decline of 15.99% in stock price over the past year [3]

Core Viewpoint - Recently, Dirui Medical (300396) announced that it received a decision from the Jilin Regulatory Bureau of the China Securities Regulatory Commission on February 5, 2026, regarding corrective measures due to improper revenue recognition from foreign sales orders [1] Summary by Categories Revenue Recognition Issues - The company improperly recognized revenue from foreign sales orders, overstating operating income by 3.69 million yuan, which accounts for 0.27% of the company's total operating income for 2023 [1] - Additionally, the company overstated operating profit by 720,000 yuan, violating relevant information disclosure management regulations [1] Regulatory Actions - The Jilin Regulatory Bureau decided to impose administrative regulatory measures requiring the company to correct its practices [1] - Warnings were issued to the company's then-General Manager Wang Xueming, Deputy General Manager Niu Dandan, and Chief Financial Officer Zhang Xingyan [1] Compliance and Internal Control - The company and the relevant personnel are required to submit a rectification report within 30 days and to strengthen internal controls to prevent similar issues from occurring in the future [1]

Core Viewpoint - The company received a decision from the Jilin Regulatory Bureau of the China Securities Regulatory Commission on February 5, 2026, regarding issues related to the recognition of revenue from foreign sales orders and internal controls [1] Group 1: Revenue Recognition Issues - The company was found to have recognized revenue from certain foreign sales orders in 2023 without the corresponding goods being actually declared for customs and subsequently returned [1] - This indicates a lack of prudence in the revenue recognition process for foreign sales orders [1] Group 2: Internal Control Deficiencies - The internal controls related to foreign sales at the company were deemed inadequate, with incomplete documentation for some foreign sales orders [1] - This highlights potential weaknesses in the company's operational processes and compliance measures [1]